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Patients and Methods: Between 10/04 and 6/06, 24 patients
(pts) with high risk/relapsed/refractory hematologic malignan-
cies have undergone NST using a modiﬁcation of our original
Pt-TBI regimen. The median age was 60 years. The median
number of prior therapies was 2 (range 0-6). Diseases trans-
planted included acute lymphoblastic leukemia (n3), myelo-
dysplastic syndrome (n2), acute myelogenous leukemia (n8),
chronic lymphocytic leukemia (n3), indolent non-Hodgkin’s
lymphoma (n2), and mantle cell lymphoma (n6). Condition-
ing consisted of Pentostatin 4 mg/m2 daily on day -10, -9, and
-8, followed by 200 cGy TBI on day -1. Post-grafting immu-
nosuppression consisted of cyclosporine/mycophenolate
mofetil. Results: Transplantation was performed using mobi-
lized progenitor cells from matched related (n8) or unrelated
(n16) donors. Death prior to 100 days post transplant oc-
curred in 4 unrelated donor transplants. The median nadir
values for hemoglobin, neutrophil count and platelet count were
8.9 g/dl (range 7.6-13.7), 300/mm3 (range 0-1900), and 63/mm3
(range 9-165) respectively. Primary graft failure/autologous re-
covery occurred in one patient with mantle cell lymphoma. The
median values for CD3 cells and WBC at day 28 were 85%
and 90% donor cells respectively. The analogous median values
at day 70 were 85% and 100% respectively. One pt with a
myelproliferative disorder and thalidomide as his only prior
therapy experienced late graft failure despite donor lymphocyte
infusions. The cumulative incidence of grade II-IV acute graft-
versus-host disease was approximately 54% (14% in related
versus 68% in unrelated donors, P0.08). The probability of
extensive chronic graft-versus-host disease in patients surviving
beyond 100 days is 38%. The cumulative incidence of relapse at
one year post transplant is 43%. The one year probabilities of
event-free and overall survival are 41% and 61% respectively.
Conclusions: This modiﬁcation of our original Pt-TBI regi-
men continues to demonstrate fairly minimal regimen related
toxicity, although as expected hematologic toxicity appears to be
more signiﬁcant than with our prior day -21 Pentostatin regi-
men. Graft versus host disease continues to be a major cause of
morbidity/mortality, particularly in unrelated donor trans-
plants. Further studies will concentrate on attempting to de-
crease the incidence of acute and chronic graft versus host
disease through the use of T-cell depletion with in vitro ale-
mtuzumab.
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UMBILICAL CORD BLOOD TRANSPLANTATION FOR ADULT PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
Brunstein, C.1, Setubal, D.1, DeFor, T.1, Weisdorf, D.1, McGlave, P.1,
Miller, J.1, Wagner, J.1 1University of Minnesota Blood and Marrow
Transplant Program, Minneapolis, MN.
Chronic myelogenous leukemia (CML) was primarily treated
with HSCT until imatinib mesilate was shown to be effective
and safe for patients with early chronic phase CML. However,
patients who fail imatinib therapy due to disease progression or
drug intolerance still require HSCT. Umbilical cord blood
(UCB) has been an increasingly used source of hematopoietic
stem cells for transplantation (HSCT) of patients with hemato-
logic malignancies who lack a suitable sibling donor. We report
here on 20 adult patients who underwent UCB transplantation
(UCBT) for Ph CML at the University of Minnesota between
1998 and 2005. Patient received myeloablative (MA, n12) or
nonmyeloablative (NMA, n8) conditioning, The median age
was 46 y (r: 18-58), 12 (60%) were male, and median weight was
78 kg (r: 57-103), and 13 (65%) were CMV positive. The MA
conditioning was Bu/Cy (n2) Cy/TBI  ATG (n4), or Cy/
Fludarabine(Flu)/TBI (n6). The NMA conditioning was Bu/
Flu/TBI (n2) or Cy/Flu/TBI ATG (n6). Posttransplanta-
tion immunosuppression was CsA alone (n1), CsA/
methylprednisolone(MP) (n5), or CsA/MMF (n14). Eleven
patients (55%) receive a double UCB graft. The highest HLA
disparity of UCB units was 4/6 (n13), 5/6 (n5), and 6/6
(n2). Six patients (30%) were in ﬁrst chronic phase (CP1) and
14 (70%) were in accelerated phase (AP) CML. The median
TNC dose infused was 2.9  107/kg (r:1.2-5.3) and median
CD34 dose infused was 4.8  105/kg (r: 0.7-12.7). The median
time from diagnosis to transplant was 24.5 months (r: 6.7-
118.8), and the median follow-up of surviving patients was 2.9
yrs (r: 0.7-.7.0). There were no failures of neutrophil engraft-
ment. In the MA setting median time to neutrophil engraftment
was 21d (r:13-33), grade II-IV acute GVHD was 58% (95%CI,
28-88%), 1-yr transplant related mortality (TRM) 41%
(95%CI, 13-69), 2-yr relapse rate 10% (95%CI, 0-26), and
overall survival 58% (95%CI, 30-86). In the NMA setting me-
dian time to neutrophil engraftment was 13d (r:5-32), grade
II-IV acute GVHD was 63% (95%CI, 28-98%), 1-yr transplant
related mortality (TRM) 38% (95%CI, 6-70), 2-yr relapse rate
13% (95%CI, 0-34), and overall survival 50% (95%CI, 15-85).
There was no statistically signiﬁcant difference between MA and
NMA conditioning regimens on all outcomes. In this report we
show that UCB appears to be a safe and effective HSC for
transplantation of patients with CML.
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FLUDARABINE/FULL DOSE I.V. BUSULFAN CONDITIONING REGIMEN IN
ALLOGENEIC PBSC TRANSPLANTATION FOR HIGH RISK PATIENTS
Chunduri, S.1, Dobogai, L.C.1, Peace, D.1, Saunthararajah, Y.1,
Quigley, J.1, Chen, Y.-H.1, Boccuni, P.1, Hoffman, R.1, Mahmud, N.1,
Beri, R.1, Hurter, E.1, Rondelli, D.1 1Section of Hematology/Oncology,
University of Illinois at Chicago, Chicago, IL.
Fludarabine/ full dose busulfan (FluBu) conditioning regimen
causes moderate extrahematologic toxicity and low rates of acute
graft-versus-host disease (GVHD) in allogeneic hematopoietic
stem cell transplantation (HSCT).
In this study we utilized this regimen in 21 adult patients with
hematologic malignancies, including 15 patients (71%) at high risk
of relapse (8 acute leukemia in relapse, 3 NHL in relapse, 1 NHL
in CR2, 1 myeloﬁbrosis in transformation, 2 CML-AP resistant to
imatinib) and 6 patients at standard risk (3 AML in CR1, 2
CML-CP resistant to imatinib, 1 MDS). All patients were prepared
with ﬂudarabine (30 or 40 mg/m2/day) for 4 days from d-9 to d-6
and i.v. busulfan (3.2 mg/kg/day) for 4 days from d-5 to d-2, and
received an HLA matched related (n14) or unrelated (n7)
peripheral blood stem cell (PBSC) transplant. Mean number of
CD34 cells infused was 7.34.0  106/kg. Thymoglobulin was
added to the preparative regimen on d -3 to d-1 in 9 patients,
including those receiving an unrelated HSCT. Acute GVHD pro-
phylaxis included standard tacrolimus and methotrexate on d1, d3,
d6 and d11. All patients fully engrafted but one ALL patient
transplanted in relapse who recovered with leukemic blasts. Me-
dian times to ANC 0.5109/L and platelet 20109/L were 15d
(range: 18-24) and 13d (range: 0-24), respectively. Acute GVHD
grade II-IV was observed in 24% of the patients (grade III-IV
18%) and chronic GVHD in 9 of 14 evaluable patients (64%). Of
21 patients, 8 died in full relapse with bacterial or fungal infection
and 2 for acute GVHD grade III and fungal infection. Median time
to relapse after HSCT was 72d (range: 18-328). At a median
follow-up of 447 d (range: 120-1196) for patients who are alive, the
overall survival (OS) and event-free survival (EFS) are 52% and
48%, respectively. In the group at high risk the OS and EFS are
both 33% at 447 d median follow-up (range: 147-834).
FluBu conditioning regimen, besides causing low transplant-
related morbidity and mortality, is also effective in high risk pa-
tients receiving an allogeneic PBSC transplant from related or
unrelated donors.
231
HAPLOIDENTICAL NON-MYELOABLATIVE HEMATOPOIETIC TRANS-
PLANT WITH SIROLIMUS BASED IMMUNOSUPPRESSION YIELDS RELI-
ABLE ENGRAFTMENT AND MAY RESULT IN LONG TERM SURVIVAL
Claxton, D.F.1, Creme, L.1, Ehmann, W.C.1, Rybka, W.B.1 1Penn
State Cancer Institute, Hershey, PA.
Timely availability of matched donors limits allo-hematopoi-
etic transplant (HCT) options for many otherwise suitable pa-
tients. We have explored sirolimus (rapamycin) based immuno-
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suppression after non-ablative conditioning for haploidentical
(3/6 and 4/6 MHC matched related donor) blood HCT. 17
patients with poor prognosis hematological malignancies re-
ceived cyclophosphamide (1gm/m2 days -7 and -6) and ﬂudara-
bine (25mg/m2 days -7 through -3) with sirolimus and tacroli-
mus, (both adjusted to 5-15ng/ml) and methotrexate (5mg/m2
days 1,3, 6) immunoprophyllaxis. Tacrolimus was tapered be-
tween days 40-100 in patients without acute GVHD. ATG
30mg/M was also given days -1,1,3, and 5. Median age was 61.
10 patients had acute leukemias, 6 had Non-hodgkins lym-
phoma and one Hodgkins disease. Only 6 patients were in
remission (CR) at the time of transplant, all of the other 11
having multiply pretreated active malignancy at HCT. Donor
cells engrafted stably in all patients (table below). 16/17
achieved 70% donor chimerism by day 30 and 11/13 90% by
day 100. 15/17 patients developed acute (d100) GVHD, but
this was grade 2 in only 4/17. In 1 patient GVHD developed
at day 121 only after discontinuation of both tacrolimus and
sirolimus. To date 2 patients remain alive free of any progres-
sion of malignancy 1216 and 1543 days post HCT. Only one of
these survivors was in CR at HCT, and this individual is now
enjoying a second remission more than 3 years longer than his
ﬁrst. 6 deaths have resulted from GVHD/Infection, while pro-
gressive malignancy (PD) has been the cause of mortality in 8
patients. One patient died of an unrelated cerebrovascular ac-
cident while free of disease or GVHD at 689 days from trans-
plant. We conclude that, while GVHD and transplant related
mortality remain obstacles, sirolimus and non-ablative condi-
tioning allow reliable engraftment of haplodentical donor HCT
with some long term survivors. These ﬁndings were in elderly
and inﬁrm patients with advanced hematological malignancy.
Engraftment of Haploidentical Cells*
D0 D15 D30 D60 D100
Mean Chimerism 0 0.73 0.88 0.94 0.98
Standard Deviation 0 0.38 0.19 0.15 0.05
Whole Blood Chimerism*
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A CRITICAL ROLE OF CD100 IN ALLOGENEIC IMMUNE RESPONSES
Duran-Struuck, R.1,2, Lowler, K.1, Beth, W.1, Luker, G.3, Liu, C.4,
Kumanogoh, A.5, Reddy, P.1, Ferrara, J.L.M.1 1University of Michigan
Cancer Center, Ann Arbor, MI; 2University of Michigan Unit for
Laboratory Animal Medicine, Ann Arbor, MI; 3University of Michigan
Dept of Microbiology & Immunology, Ann Arbor, MI; 4University of
Florida College of Medicine, Gainesville, FL; 5Osaka University, Osaka,
Japan.
Sema4D (CD100) is a novel 150 kDa protein that belongs to
the semaphorin family and has recently been shown to modulate
autoimmunity. We tested the requirement of CD100 expression
on T cells in regulating allo-immune responses. When alloge-
neic BALB/c stimulators were cultured with responder cells
from either wild type(wt) B6 or CD100 deﬁcient-/-B6, T cells
from the CD100-/-animals showed a ten fold less expansion
than the WT controls(10,800 /- 1,230 vs. 1,600 /- 258 cpm
p0.01). Consistent with the reduced proliferation, CD100-/-
T cells produced less IFN (1890 pg/mL) compared to B6 wt
Tcells (3478pg/mL) (p0.01). Similar reduction in prolifera-
tion and IFN  production was observed using anti-CD100
mAb’s (data not shown). We next determined the in vivo rele-
vance of CD100 expression on T cell allogeneic responses in a
well characterized experimental model of GVHD. We utilized
the B6(H2b) --BALB/c (H2 d) model where the donor and
recipient are mismatched at both major and minor histocom-
patibility antigens. Recipient BALB/c animals were irradiated
with 8Gy and transplanted with 5.0106 million bone marrow
(BM) cells from wtB6 animals together with 0.5 million T cells
from either wtB6 or CD100 -/- donors. Allogeneic recipients
that were injected with CD100 -/- donor Tcells showed signif-
icantly reduced mortality, less clinical and GVHD speciﬁc tar-
get organ damage (see table). Similar beneﬁt in the reduction of
GVHD was observed with anti-CD100 mAb treatment into the
recipients. When BALB/c recipient mice were challenged with
the P815 (H2 d) murine mastocytoma cell line and received wt
or CD100-/- B6 T cells, there was a signiﬁcant improvement in
the tumor free survival when compared to syngeneic recipients
thus demonstrating preservation of graft-versus-leukemia (90%
survival in allogeneic vs. 0% survival in syngeneic on day 12
post BMT p0.05). We next tested the hypothesis that absence
of CD100 expression on Tcells reduced the function of alloge-
neic APCs. When BALB/c DCs were treated with LPS and
co-cultured with CD100-/- B6 T cells, they secreted less
amounts of TNFa and IL12p70 compared to co-culture with wt
B6 Tcells (table). Use of antiCD100 mAb’s showed similar
results. In conclusion, we demonstrate a novel role for CD100
in regulating in vitro and in vivo allogeneic responses using these
two complementary approaches.






(day  60) 4.6/-0.8 1.8/-0.2 <0.02
Survival (day  60) 55% 100% <0.05
Liver Pathology (day
 60) 17.0/-1.5 9.0/-1.3 <0.01
Skin Pathology (day
 60) 1.5/-0.2 0.8/-0.2 0.02
Intestinal Pathology




post BMT 584/-148 286/-97 <0.06
IFNg in vitro 3477/-254 1889/-221 <0.01
DC IL-12p70 in vitro 107/-7 68.5/-2 <0.01
DC TNFa in vitro 5930/-123 4252/-233 <0.01
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CD34 DOSE AND CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
AFFECT SURVIVAL IN ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION (ALLOPBSCT) FOLLOWING NON-MYELOABLATIVE
(NM) CONDITIONING: THE VANDERBILT UNIVERSITY/NASHVILLE VA
SCT PROGRAM EXPERIENCE
Ewing, G.1,2, Giglia, J.1,2, Vusirikala, M.2, Ye, F.1, Shyr, Y.1,
Chinratanalab, W.1,2, Ruffner, K.1,2, Kassim, A.1, Jagasia, M.1,
Engelhardt, B.1, Brandt, S.1,2, Morgan, D.1,2, Stein, R.1, John, G.1,
Schuening, F.1, Goodman, S.1,2 1Vanderbilt University Medical Center,
Nashville, TN; 2Nashville Veterans Administration/Tennessee Valley
Healthcare System, Nashville, TN.
AlloPBSCT utilizing NM conditioning is hypothesized to
minimize the toxicity of myeloablative regimens while harness-
ing a potent graft vs malignancy effect. We sought to identify
factors predicting survival in a retrospective analysis of 60 pa-
tients (pts) undergoing alloPBSCT from HLA-matched related
donors between 8/00 and 8/05 at our program. All pts received
90 mg/m2 ﬂudarabine and 200 cGy TBI. GVHD prophylaxis
consisted of CSA/MMF. The median age was 55 years (range
41-66). Male: female was 51:9. All transplants were performed
for hematologic malignancies. The median number of treat-
ments prior to transplant was 4 (range 0-8). The mean cell doses
infused were 8.0 (range 3.5-16.3) x 106 CD34/kg and 28.4
(range 0.9-65.9) x 107 CD3/kg. Among 33 (55%) pts who
became neutropenic, the median time to ANC  500 was 21
days (range 14-49). Primary graft failure occurred in 2 patients.
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